| Product dosage: 20mg | |||
|---|---|---|---|
| Package (num) | Per pill | Price | Buy |
| 60 | $0.72 | $43.06 (0%) | 🛒 Add to cart |
| 90 | $0.67 | $64.60 $60.09 (7%) | 🛒 Add to cart |
| 120 | $0.63 | $86.13 $76.11 (12%) | 🛒 Add to cart |
| 180 | $0.61 | $129.19 $109.16 (16%) | 🛒 Add to cart |
| 270 | $0.59 | $193.79 $159.23 (18%) | 🛒 Add to cart |
| 360 | $0.58
Best per pill | $258.38 $209.31 (19%) | 🛒 Add to cart |
Synonyms
| |||
Similar products
More info:
tamoxifen
Tamoxifen citrate represents one of the most significant advances in endocrine oncology, a selective estrogen receptor modulator (SERM) that fundamentally changed breast cancer management. Initially developed in the 1960s, this synthetic non-steroidal agent created an entirely new therapeutic paradigm—blocking estrogen’s proliferative effects in breast tissue while acting as an agonist in other tissues like bone and endometrium. The clinical implications were staggering, moving breast cancer treatment beyond crude cytotoxics into targeted hormonal manipulation.
Androxal: Evidence-Based Testosterone Optimization for Hypogonadism - Clinical Review
Androxal represents one of the more interesting developments in male endocrinology we’ve seen in recent years—it’s not your typical testosterone booster. The product is actually enclomiphene citrate, the trans-isomer of clomiphene, functioning as a selective estrogen receptor modulator (SERM) with predominantly estrogen antagonist effects in certain tissues. Unlike traditional testosterone replacement therapies (TRT) that can suppress natural luteinizing hormone (LH) and follicle-stimulating hormone (FSH) production, Androxal works upstream at the hypothalamic-pituitary level to stimulate endogenous testosterone production.
Arimidex: Estrogen Suppression for Breast Cancer Treatment - Evidence-Based Review
Anastrozole, marketed under the brand name Arimidex, represents a cornerstone in the endocrine therapy arsenal for hormone receptor-positive breast cancer. This non-steroidal aromatase inhibitor specifically targets the aromatase enzyme, which is responsible for the peripheral conversion of androgens to estrogens in postmenopausal women. By effectively suppressing estrogen production to near-undetectable levels, Arimidex creates an unfavorable environment for estrogen-dependent tumor growth. The clinical significance of this mechanism cannot be overstated—it has fundamentally altered the treatment paradigm for hormone-sensitive breast malignancies, offering both adjuvant and metastatic treatment options with demonstrated survival benefits.
Aromasin: Potent Estrogen Suppression for Breast Cancer - Evidence-Based Review
Aromasin, known generically as exemestane, is a steroidal aromatase inactivator used primarily in postmenopausal women with hormone receptor-positive early or advanced breast cancer. It functions by irreversibly binding to the aromatase enzyme, which is responsible for converting androgens into estrogens in peripheral tissues. By lowering circulating estrogen levels, Aromasin effectively starves estrogen-dependent tumor cells of the hormonal stimulation they require for growth and proliferation. This oral medication represents a cornerstone of endocrine therapy, particularly following failure of tamoxifen therapy, and has demonstrated significant efficacy in improving disease-free survival and reducing contralateral breast cancer incidence.
clomid
Clomiphene citrate, commonly known by its brand name Clomid, represents one of the foundational pillars in reproductive endocrinology. This selective estrogen receptor modulator (SERM) has been revolutionizing fertility treatments since the 1960s, yet many clinicians still don’t fully appreciate its nuanced applications beyond basic ovulation induction. What started as a simple ovulation-inducing agent has evolved into a sophisticated tool for managing various hypothalamic-pituitary-gonadal axis disorders. The standard 50mg tablet formulation contains the racemic mixture of enclomiphene and zuclomiphene isomers, though the enclomiphene component demonstrates significantly greater estrogen antagonist activity.
enclomisign
Enclomisign represents one of the more fascinating developments in male reproductive endocrinology we’ve seen in the last decade. It’s not your typical testosterone replacement therapy—rather than adding exogenous hormones, it works by stimulating the body’s own testosterone production through selective estrogen receptor modulation. The compound started showing up in compounding pharmacies around 2015, and we’ve been tracking its effects in our clinic since 2017. What’s interesting is how it evolved from research on enclomiphene citrate, the trans-isomer of clomiphene, with better receptor specificity and fewer side effects.
Eulexin: Effective Androgen Blockade for Prostate Cancer - Evidence-Based Review
Flutamide, marketed under the brand name Eulexin among others, is a nonsteroidal antiandrogen medication primarily used in the management of prostate cancer. It works by competitively blocking the effects of androgens like testosterone and dihydrotestosterone (DHT) on their receptors, thereby inhibiting the growth of androgen-sensitive prostate cancer cells. Eulexin is typically administered in combination with a luteinizing hormone-releasing hormone (LHRH) agonist as part of combined androgen blockade therapy for advanced prostate cancer.
evista
Raloxifene hydrochloride, marketed as Evista, represents one of the more nuanced tools in our endocrinology arsenal—a selective estrogen receptor modulator (SERM) that paradoxically acts as both agonist and antagonist depending on the tissue. When I first encountered this medication during my fellowship, the pharmacology seemed almost contradictory: bone-protective like estrogen but blocking estrogen effects in breast and uterine tissue. Over fifteen years of managing osteoporosis and reducing breast cancer risk in high-risk postmenopausal women, I’ve watched Evista evolve from a promising newcomer to an established option with very specific indications and limitations.
Femara: Effective Hormone Therapy for Breast Cancer - Evidence-Based Review
Letrozole, marketed under the brand name Femara among others, is an oral non-steroidal aromatase inhibitor used primarily in the treatment of hormone receptor-positive breast cancer in postmenopausal women. It works by significantly reducing estrogen production in the body, which can slow or stop the growth of certain types of breast cancer tumors that require estrogen to proliferate. Beyond its primary oncology indications, letrozole has established roles in ovulation induction for fertility treatment, representing a significant shift from previous first-line therapies.